November 3, 2008 - LifeNet Health received 510(k) clearance from the FDA for CardioGraft allograft cardiac patch products with MatrACELL decellularization technology.

LifeNet Health received clearance for the technology for cardiac products, which safely removes donor cells from cardiovascular tissues while retaining the native biomechanical strength of the tissue.

The company said the clearance strengthens LifeNet Health’s position in the pediatric cardiac reconstruction market.

November 3, 2008 - ACIST Medical Systems Inc. (a Bracco Group company), signed a distribution agreement for the StatSensor Creatinine Meter with Nova Biomedical, in which the ACIST and Nova teams will co-exclusively market and distribute the StatSensor Creatinine Meter into the medical fields of radiology and cardiology within North America.

November 3, 2008 – PETNET Solutions, a wholly-owned subsidiary of Siemens Medical Solutions USA, and Covidien have entered into a co-marketing agreement to offer a combined portfolio of high-energy and low-energy radioisotopes to the nuclear medicine community in the U.S.

November 3, 2008 - CardioNet Inc. a wireless medical technology company with a focus on the diagnosis and monitoring of cardiac arrhythmias, today said the Centers for Medicare and Medicaid Services (CMS) has established reimbursement rates that cover the CardioNet System.

Toshiba's Infinix-i floor mounted, 5-axis system is a cardiovascular lab featuring patient access and coverage, making it possible to obtain images without repositioning patients. The system includes a high-definition flat panel detector and the new Advanced Image Processing (AIP) technology that enhances the display of small details, including intricate blood vessels and small devices, such as catheters. The Infinix–i 5-axis system is available with different size flat panel detectors to perform cardiac and vascular procedures.

A new ultrasound system for radiology and vascular applications, the LOGIQ E9, fuses ultrasound images with images from other imaging modalities like CT and MR.

Lantheus Medical Imagings Definity perflutren lipid microsphere ultrasound contrast agent
Lantheus Medical Imagings Definity perflutren lipid microsphere ultrasound contrast agent
Lantheus Medical Imagings Definity perflutren lipid microsphere ultrasound contrast agent

Proponents and researchers of microbubble contrast-enhanced cardiac ultrasound say the technology will eventually evolve to match the diagnostic quality of CT and nuclear perfusion images without the radiation and at a faction of the cost.

Cardiovascular care does not occur in a single hospital setting; more often than not patients undergo a variety of tests at different locations. In order to provide the best care possible, physicians need immediate access to all patient information, no matter where, when or how it was obtained.


There is considerable interest in being able to clearly identify vulnerable plaque (VP) and research efforts are intensifying. Several invasive imaging technologies claim to detect VP, and while the link between VP identification, plaque rupture and clinical events has yet to be firmly established, progress is being made in the research.

Going into 2009, proponents of coronary CT angiography (CTA) are confident that the scan’s ever-increasing acceptance will lead to it becoming the gold standard in imaging for patients with low or intermediate risk of coronary artery disease. From a business perspective, the CTA remains a driving force in the cardiac CT market.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now